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Abstract
Background: Drug-Drug Interactions between Non Steroidal Anti-Inflammatory Drugs (NSAIDs) and Angiotensin Converting
Enzyme Inhibitors (ACEIs), Angiotensin Receptor Blocker (ARBs) or diuretics can lead to renal failure and hyperkalemia. Thus,
monitoring of serum creatinine and potassium is recommended when a first dispensing of NSAID occur in patients treated
with these drugs.
Methods: We conducted a pharmacoepidemiological retrospective cohort study using data from the French Health
Insurance Reimbursement Database to evaluate the proportion of serum creatinine and potassium laboratory monitoring in
patients treated with ACEI, ARB or diuretic and receiving a first dispensing of NSAID. We described the first dispensing of
NSAID among 3,500 patients of a 4-year cohort (6,633 patients treated with antihypertensive drugs) and analyzed serum
creatinine and potassium laboratory monitoring within the 3 weeks after the first NSAID dispensing.
Results: General Practitioners were the most frequent prescribers of NSAIDs (85.5%, 95% CI: 84.3–86.6). The more commonly
prescribed NSAIDs were ibuprofen (20%), ketoprofen (15%), diclofenac (15%) and piroxicam (12%). Serum creatinine and
potassiummonitoringwas10.7%(95%CI:9.5–11.8)inpatientstreatedbyACEIs,ARBsordiuretics.Overall,monitoringwasmore
frequently performed to women aged over 60, treated with digoxin or glucose lowering drugs, but not to patients treated with
ACEIs, ARBs or diuretics. Monitoring was more frequent when NSAIDs’ prescribers were cardiologists or anesthesiologists.
Conclusion: Monitoring of serum creatinine and potassium of patients treated with ACEIs, ARBs or diuretics and receiving a
first NSAID dispensing is insufficiently performed and needs to be reinforced through specific interventions.
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Introduction
Because Non Steroidal Anti-Inflammatory Drugs (NSAIDs)
inhibit cyclooxigenase enzymes (COX) and prevent prostaglandin
synthesis, their drug-drug interactions (DDIs) with antihyperten-
sive drugs can lead to adverse drug reactions [1]. NSAIDs
association with these drugs can increase arterial blood pressure.
Concomitant use of NSAIDs with Angiotensin Conversion
Enzyme inhibitors (ACEIs), Angiotensin Receptors Blockers
(ARBs) or diuretics can also precipitate acute renal failure,
hyponatremia or hyperkalemia, especially when used on elderly
or dehydrated individuals. Moreover, the risk of significant renal
impairment is associated with the number of these drugs, when
they are associated [2].
In France, two drug interaction compendia are available. The
main one is provided by the Agence Franc ¸aise de Se ´curite ´ Sanitaire et des
Produits de Sante ´ (Afssaps, the French Drug Agency) and is available
online [3]. The concise information provided in this guideline is
used by the main drug databases (especially the French National
Formulary: VidalH [4]). The second one is the annual supplement
of the French independent drug information bulletin La Revue
Prescrire [5]. Recommendations are to monitor serum creatinine
alone [4], and even serum creatinine and potassium [5] whenever
NSAIDs are first prescribed with ACEIs, ARBs or diuretics (Table
S1). However, prescribers’ compliance to these recommendations
had not been fully evaluated. Thus, we performed a pharmacoe-
pidemiological cohort study investigating if these laboratory
monitoring are currently followed by practitioners.
Methods
All the French population is covered by a publicly funded health
system. The French Health Insurance Reimbursement Database
gathers information concerning these patients. Four kinds of data
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e34187are computerized in this database: demographic characteristics of
users, characteristics of health professionals, data concerning
health facilities and reimbursement data (drug, laboratory,
radiology, medical acts) [6]. Concerning drug dispensing, the
database contains information on the date of dispensing, quantity
dispensed, and prescriber. Drugs are classified according to the
Anatomical Therapeutic Chemical system [7].
Study population
We extracted a random sample of patients (sample rate: 5%, as
provided by the French Health Insurance System Database), living
in the Midi-Pyre ´ne ´es area (2,600,000 inhabitants) between 1 April
2005 and 1 April 2006, receiving at least two prescriptions of the
same antihypertensive drug and not receiving any NSAID
(including topical, injectable and oral forms) during this period.
Inclusion in the study was on 1 April 2006 for all patients and the
maximal follow-up was 4 years (until 31 March 2010, because of
database size limitations). Patients were considered lost-to-follow-
up if having no drug dispensing for more than 3 months. All data
were anonymous in conformity with the French Law of Privacy (8).
The following oral and injectable NSAIDS marketed in France
during the period of study were extracted: arylcarboxylic acids
(aceclofenac, alminoprofen, diclofenac, etodolac, fenoprofen,
flurbiprofen, ibuprofen, ketoprofen, naproxen, nabumetone,
tiaprofenic acid), oxicams (meloxicam, piroxicam, tenoxicam),
coxibs (celecoxib), acetylsalicylic acid (excluding anti-platelet
doses) and others (indometacin, sulindac, phenylbutazone, nime-
sulide, mefenamic acid, morniflumate, niflumic acid).
Antihypertensive drugs included beta-blocking agents, ACEI,
ARBs, diuretics (except eplerenone), calcium channel blockers
(except bepridil), alpha-blocking agents or other drugs (centrally
acting antihypertensive drugs, minoxidil and dihydralazine). Renin
inhibitors were not available in France during the period of study
and thus were not included in the analysis. We took into account
fixed combinations of antihypertensive drugs as separate drugs.
The level of renal failure and hyperkalemia risk caused by
NSAID/antihypertensive DDIs was graduated in risk levels, as
showed in table 1.
For chronically used drugs, data were extracted between 6
months before and 6 months after the first NSAID dispensing.
Patients were considered exposed between the first and the last
dispensing of these drugs in this one-year time frame.
Laboratory monitoring of serum creatinine and potassium were
considered relevant if occurring within 3 weeks after the start of
NSAID. This time frame is pharmacologically relevant and
already used in monitoring of initiation or intensification of Renin
Angiotensin System Inhibitors (RASIs) [8]. We also explored
laboratory monitoring before start of NSAID with monitoring
occurring in the year previous first prescription of NSAID.
Ethics/consent
We performed an observational study on anonymous data.
Thus, considering the French legislation, it does not need to be
approved by an ethic committee.
Statistic analysis
Descriptive statistics were computed to characterize patients,
drug dispensing, and laboratory monitoring. Factors associated
with laboratory monitoring in univariate analysis (p,0.2) were
assessed using logistic regression modeling. Characteristics con-
sidered in univariate models included age, gender, level of renal
failure and hyperkalemia risk caused by DDIs with antihyperten-
sive drugs, digoxin, potassium supplements, glucose lowering
drugs, platelet anti-aggregating agents, hospitalizations in the three
months previous first dispensing of NSAIDs. Statistical analyses




Over the 6,633 patients of the cohort, 3,622 had a first
dispensing of NSAIDs during the follow-up (incidence rate: 25.1/
100 PY). Among them, 122 were not treated with antihypertensive
drug anymore when the first dispensing of NSAIDs occurred and
were thus excluded from the analysis (figure 1). Among the 3,500
remaining patients, 22 had a first dispensing of two different
NSAIDs, always prescribed by the same physician. The charac-
teristics of the first dispensing of NSAIDs are shown in table 2.
Overall, 2,696 (77.0%) patients were classified at risk of DDI («one
drug»: 41.6%, «two drugs»: 35.3%). General Practitioners (GPs)
prescribed the majority of NSAIDs (85.5%, 95% CI: 84.3–86.6),
and mainly ibuprofen (18.6%), diclofenac (16.3%), ketoprofen
(15.4%) or piroxicam (13.4%). Dentists preferentially prescribed
ibuprofen (52.2%) and surgeons mainly prescribed ketoprofen
(15.2%). Cardiologists and anesthesiologists mainly prescribed
flurbiprofen (76.9% and 90.5% of their NSAIDs prescriptions).
Serum creatinine and potassium monitoring
Baseline complete monitoring was performed in 59.1% (95%
CI: 57.3–61.0) of patients treated by ACEIs, ARBs or diuretics (‘‘at
risk’’ group). In only 10.7% (95% CI: 9.5–11.8) of these patients, a
complete laboratory monitoring was recorded in the three weeks
after NSAID initiation. This monitoring occurred by mean on the
8
th day (8.566.1) after the first dispensing of NSAID. Table 3
shows the different rates of monitoring according to DDIs risks.
Univariate analysis showed that all the characteristics selected
were associated to serum creatinine and potassium monitoring
(table 4). Multivariate analysis performed with these variables
(table 5), showed that being aged over 60 (60–70: OR=1.78, 95%
CI: 1.00–3.15; 70–80: OR=2.17, 95% CI: 1.26–3.73; over 80:
OR=3.14, 95% CI: 1.79–5.48) and a woman (OR=1.26, 95%
CI: 1.00–1.59) was associated with a more frequent monitoring.
Monitoring was also more frequent among patients treated with
potassium supplements (OR=2.47, 95% CI: 1.49–4.12) and
glucose lowering drugs (OR=1.58, 95% CI: 1.22–2.06) but not in
patients treated with ACEI, ARBs or diuretics («one drug»
OR=1.27, 95% CI: 0.92–1.75; «two drugs» OR=1.28, 95% CI:
Table 1. Risk of renal failure/hyperkalemia caused by DDIs
with NSAIDs according to classes of antihypertensive drugs.
Risk group Antihypertensive classes




At risk of DDI
{
«one drug» Diuretics or ACEI or ARB
«two drugs and more» Diuretics + ACEI/ARB
DDI, Drug-Drug Interaction; ACEIs, angiotensin converting enzyme inhibitors;
ARBs, angiotensin receptor blockers.
{At risk of renal failure/hyperkalemia caused by Drug-Drug Interactions (DDIs)
between NSAIDs and antihypertensives.
doi:10.1371/journal.pone.0034187.t001
NSAIDs Interactions and Laboratory Monitoring
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doi:10.1371/journal.pone.0034187.g001
Table 2. Characteristics of the first dispensing of NSAID.
Characteristics NSAID (all) Ibuprofen Ketoprofen Diclofenac Piroxicam Celecoxib
Acetylsalicylic
Acid
Number of patients, n (%) 3,500 (100.0) 722 (20.6) 531 (15.2) 526 (15.0) 416 (11.9) 124 (3.5) 144 (4.1)
DDD dispensed, n (m 6 sd) 13.567.8 7.563.9 18.468.1 17.366.2 13.865.2 28.166.9 5.863.0
Time since index date,
d (med [IQR])
376 [170–718] 418 [208–786] 404 [174–828] 444 [194–787] 258 [128–480] 476 [176–833] 321 [169–622]
Prescriber, n (%)
General Practitioner 2.992 (85.5) 560 (77.6) 464 (87.4) 492 (93.5) 403 (96.9) 116 (93.5) 139 (96.5)
Dentist 274 (7.8) 143 (19.8) 12 (2.3) 4 (0.8) 1 (0.2) 0 (0.0) 1 (0.7)
Other prescribers 230 (6.6) 18 (2.5) 55 (10.3) 30 (5.7) 12 (2.9) 8 (6.4) 4 (2.8)
Surgeons 76 (2.2) 11 (1.5) 31 (5.8) 13 (2.5) 0 (0.0) 0 (0.0) 0 (0.0)
Rheumatologist 57 (1.6) 2 (0.3) 12 (2.3) 9 (1.7) 6 (1.4) 6 (4.8) 1 (0.7)
Anesthesiologist 21 (0.6) 0 (0.0) 1 (0.2) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Cardiologist 13 (0.4) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (1.4)
Other 67 (1.9) 5 (0.7) 10 (1.9) 8 (1.5) 6 (1.4) 0 (0.0) 0 (0.0)
Missing 4 (0.1) 1 (0.1) 1 (0.2) 0 (0.0) 0 (0.0) 2 (1.6) 1 (0.7)
Antihypertensive drug DDI risk, n (%)
No risk 804 (23.0) 168 (23.3) 122 (23.0) 115 (21.9) 95 (22.8) 24 (19.3) 33 (22.9)
At risk of DDI
{ 2,696 (77.0) 554 (76.7) 409 (77.0) 411 (78.1) 321 (77.2) 100 (80.6) 111 (77.1)
«one drug» 1,460 (41.7) 289 (40.0) 219 (41.2) 214 (40.7) 190 (45.7) 57 (46.0) 59 (39.6)
«two drugs and more » 1,236 (35.3) 265 (36.7) 190 (35.8) 197 (37.4) 131 (31.5) 43 (34.7) 54 (37.5)
n, number; m, mean; sd, standard deviation; d, days; med, median; IQR, interquartile range; DDI Drug-Drug interaction.
NSAIDs, non steroidal anti-inflammatory drugs; DDD, defined Daily Dose;
Acetylsalicylic Acid: excluding anti-platelet dose.
{At risk of renal failure/hyperkalemia caused by Drug-Drug Interactions (DDIs) between NSAIDs and antihypertensives (see table 1).
doi:10.1371/journal.pone.0034187.t002
NSAIDs Interactions and Laboratory Monitoring
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NSAID was a cardiologist or an anesthesiologist (OR=3.32, 95%
CI: 1.53–7.26).
Discussion
Our study was performed to evaluate the implementation of
laboratory monitoring in patients treated with ACEI/ARB/
Diuretic plus NSAID. Our results show that despite well-known
potential biochemical disturbances, serum creatinine and potassi-
um monitoring were recorded in less than 11% of patients at risk.
Monitoring occurred at day 8 and was more frequently performed
to women aged over 60, treated with potassium supplements or
glucose lowering drugs, but not to patients treated with ACEI,
ARBs or diuretics. Monitoring was more frequent when NSAIDs’
prescriber was a cardiologist or anesthesiologist.
The characteristics of NSAID prescriptions are close to the
ones found in a monthly prevalence descriptive study leaded in
the same area in 2006 [9]. First prescriptions of NSAIDs among
hypertensive patients do not differ from NSAIDs prescriptions in
general population, as the more frequently prescribed NSAIDs
are in both studies ibuprofen, ketoprofen, diclofenac and
piroxicam. Our study adds information on specificities of
NSAIDs’ prescriptions among prescribers. Among GPs, the rate
of piroxicam prescriptions remains high, but is decreasing
compared to previous studies performed in the same area [10].
This phenomenon may reflect the recent recommendation from
the Haute Autorite ´ de Sante ´ (equivalent of the National Institute for
Health and Clinical Excellence in France), underlining that
piroxicam remains a second-line NSAID [11] in its main
indications. We also found that dentists’ prescriptions were
preferentially ibuprofen, the NSAID commonly prescribed for its
anti-inflammatory and analgesic effect in acute dental pain [12].
This information is reassuring, as low dose ibuprofen is believed
to be (with naproxen) the least harmful NSAID regarding
cardiovascular events [13].
To our knowledge, this study is the first one describing
monitoring of serum creatinine and potassium in patients at risk
of renal failure or hyperkalemia caused by NSAID DDIs with
ACEI, ARBs or diuretics. The rate found in our study (around
11%) is unsurprisingly low. Low monitoring rates have been found
in previous study whether in RASIs initiation (34% of control in
the first 3 weeks [8]) or with chronically prescribed ARBs/ACEIs/
diuretics (68 to 72% of annual control [14]). Furthermore, in our
study the level of DDIs risk is not associated with a greater control.
In Bootsma et al. study [8], being under NSAIDs was not
associated to an adequate control either in patients starting ACEI/
ARB therapy.
Table 3. Serum creatinine and potassium monitoring before* and after start of NSAID.
{
















(n=1.942) (n=534) (n=374) (n=347) (n=532) (n=374)
No risk, 804 348 (43.3) 511 (63.6) 367 (45.6) 59 (7.3) 109 (13.6) 66 (8.2)
At risk of DDI
{, 2,696
«one drug», 1,460 833 (57.0) 1,038 (71.1) 870 (59.6) 154 (10.5) 225 (15.4) 164 (11.2)
«two drugs and more», 1,236 761 (61.6) 880 (71.2) 792 (64.1) 134 (10.8) 198 (16.0) 142 (11.5)
NSAIDs, non steroidal anti-inflammatory drugs.
*in the year previous first NSAID dispensing.
{in the 3 weeks after start of NSAID.
{At risk of renal failure/hyperkalemia caused by Drug-Drug Interactions (DDIs) between NSAIDs and antihypertensives (see table 1).
doi:10.1371/journal.pone.0034187.t003
Table 4. Serum creatinine and potassium monitoring after start of NSAID according to NSAID prescriber.
NSAID Prescriber (n) Laboratory monitoring after start of NSAID* [n (%)]
Creatinine and potassium monitoring Creatinine monitoring Potassium monitoring
(n=347) (n=532) (n=372)
General Practitioner (2,992) 294 (9.8) 459 (15.3) 317 (10.6)
Dentist (274) 24 (8.8) 35 (12.8) 24 (8.8)
Other prescribers (238) 29 (12.2) 38 (16.0) 31 (13.0)
Anesthesiologist (21) 4 (19.0) 7 (33.3) 5 (23.8)
Cardiologist (13) 5 (38.5) 5 (38.5) 5 (38.5)
Surgeons (76) 9 (11.8) 14 (18.4) 9 (11.8)
Rheumatologist (56) 3 (5.4) 4 (7.1) 3 (5.4)
Other (67) 8 (12.5) 8 (12.5) 9 (14.1)
NSAIDs, non steroidal anti-inflammatory drugs.
doi:10.1371/journal.pone.0034187.t004
NSAIDs Interactions and Laboratory Monitoring
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guidelines for DDIs between NSAIDs and antihypertensives. This
finding is quite ambiguous, as GP have previously reported their
concerns about NSAIDs safety of use in daily practice and claimed
a caution approach in NSAID prescription [15]. As an
explanation to this phenomenon, two approaches can be
considered focusing on guideline-related factors and GPs-related
factors [16]. Concerning the quality of the interaction compedia,
one should underline that the main one, provided by the French
Drug Agency, is available online [3]. The concise information
provided in this guideline is used by the main drug databases
(especially the French National Formulary: VidalH [4]) and thus in
the main medical software, which automated prompts and alerts
have already demonstrated positive effects on decreasing prevent-
able adverse drug events [17]. The main limitation of the
recommendations could be the absence of explicit time frame in
which the monitoring should be performed. The impact of this
lack of precision remains uncertain. Moreover, the recommenda-
tions are different in other compendia. Surprisingly, the British
National Formulary emphasizes on the increased risk of nephrotox-
icity of the association between NSAIDs and ACEIs/ARBs/
diuretics, [18] but does not provide recommendations of
laboratory monitoring. This lack of consistency between drug
interaction compendia has already been raised [19] and underlines
the necessity for their standardization.
Regarding GPs-related factors for the non-implementation of
drug prescribing guidelines, GPs may consider guidelines as too
stringent in general. They consider laboratory monitoring as time-
consuming, especially when they are uncertain that monitoring
was already performed by another provider [20]. GPs also raise
concerns about the real impact of computerized clinical decision
support to increase implementation of guidelines, as a phenom-
enon of alert fatigue could occur. Weingart et al. [21] recently
emphasized on the necessity for computerized alerts to be adapted
to clinicians.
In the present study, cardiologists and anesthesiologists
prescribed more frequently adequate monitoring. This phenom-
enon can be explained by an increased prescription of flurbiprofen
within these two medical specialties. Flurbiprofen is marketed in
France for prevention of reinfarction and reocclusion after
successful thrombolysis or angioplasty in acute myocardial
infarction, in patients for whom aspirin is not recommended
[22]. Thus, these patients could have more frequent monitoring
because of their condition. Another explanation could be that
these medical specialties are more aware of the risk evaluated in
the present study.
Limitations
The use of the French Health Insurance Reimbursement
Database in pharmacoepidemiological studies has already been
fully described [6], but it implies some limitations. As for many
administrative databases, we did not have access to medical
characteristics of the patients. This involves using medications as
proxies of morbidities (e.g. glucose lowering drugs for diabetes
mellitus [23]). We were not able to extract some characteristics
associated to serum creatinine and potassium monitoring in a
previous study [24], because of database limitations. In this study
of Raebel et al., increasing number of outpatient visits and
diagnoses of chronic heart failure or kidney disease were associated
to annual monitoring. Furthermore, the disease necessitating
NSAID prescription could alone be a condition implying a
monitoring of serum creatinine and potassium (e.g. renal colic
Table 5. Factors associated with serum creatinine and potassium after start of NSAID.
Factors Unadjusted odds ratio p Adjusted odds ratio* p
[95% confidence interval] [95% confidence interval]
Age, years (,50 years as reference)
50–60 1.70 [0.94–3.07] 0.075 1.64 [0.91–2.95] 0.147
60–70 1.89 [1.07–3.34] 0.028 1.78 [1.00–3.15] 0.049
70–80 2.51 [1.44–4.36] 0.001 2.31 [1.32–4.04] 0.003
.80 3.42 [1.94–6.03] 0.000 3.36 [1.90–5.96] 0.000
Gender (male as reference) 1.18 [0.95–1.48] 0.129 1.26 [1.00–1.59] 0.044
Concomitant drugs
{
Potassium supplements 2.88 [1.74–4.75] 0.000 2.47 [1.49–4.12] 0.001
Glucose lowering drugs 1.58 [1.22–2.04] 0.001 1.58 [1.22–2.06] 0.001
Digoxin 2.04 [1.17–3.54] 0.012 1.60 [0.91–2.82] 0.106
Platelet aggregation inhibitors 1.49 [1.17–1.88] 0.001 1.20 [0.93–1.54] 0.153
Risk level of DDI
{ (no risk as reference)
One drug 1.49 [1.09–2.04] 0.013 1.27 [0.92–1.75] 0.139
Two drugs 1.53 [1.11–2.11] 0.009 1.28 [0.92–1.77] 0.140
Hospitalizations
1 (any) 2.68 [1.14–6.27] 0.023 2.09 [0.87–5.00] 0.097
NSAID prescriber
Cardiologist or Anesthesiologist
" 3.33 [1.54–7.19] 0.002 3.32 [1.53–7.26] 0.003
*Adjusted for age, gender, exposure to potassium supplements, glucose lowering drugs and NSAIDs prescriber.
{according to ATC classification.
{Risk level of renal failure/hyperkalemia caused by Drug-Drug Interactions (DDIs) between NSAIDs and antihypertensives (see table 1).
1in the 6 months before inclusion.
"Compared to other prescribers.
doi:10.1371/journal.pone.0034187.t005
NSAIDs Interactions and Laboratory Monitoring
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been performed and not all the ones that have been prescribed. A
lot of patients-related situations (reluctance to blood test, doctor
shopping, excessive self-confidence towards adverse drug reac-
tions…) could have an impact on the realization of monitoring in a
reasonable time frame.
Finally, the low prevalence of complete monitoring could have
been underestimated. In our study, we only have access to
ambulatory biochemical monitoring and thus could have missed
the ones realized during hospitalizations. On the other hand, one
could have underestimated the prevalence of ibuprofen and
aspirin consumption, as these specific NSAIDs can be sold out-of-
the-counter and thus not recorded in the French Health Insurance
Reimbursement Database.
Conclusion
The low prevalence of serum creatinine and potassium
monitoring shows a very poor implementation of guidelines.
Further studies are required to correlate this low prevalence with a
potential increased risk of severe adverse drug reactions.
Moreover, intervention studies are required to improve the
knowledge of this specific risk, especially among GPs.
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Table S1 Drug interactions between NSAIDs and anti-
hypertensive drugs according to l’Agence Franc ¸aise de
Se ´curite ´ Sanitaire et des Produits de Sante ´ (=French
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